Skip to main content
OpenTrials

Clinical trial condition

Metastatic Renal Pelvis Urothelial Carcinoma

Explore clinical trials studying Metastatic Renal Pelvis Urothelial Carcinoma. Study availability and eligibility vary by location and protocol.

10 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Metastatic Renal Pelvis Urothelial Carcinoma trial results

Completed

Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer

NCT00942331

Conditions
Advanced Urothelial Carcinoma, Carcinoma, Carcinoma, Transitional Cell, +32 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Providence Hospital Mobile, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • University of Arizona Cancer Center-Orange Grove Campus Tucson, Arizona, United States
View all 873 locations
View Trial Details
Completed

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

NCT03513952

Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Carcinoma, +40 more
Locations
  • Kaiser Permanente-Riverside Riverside, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Straub Clinic and Hospital Honolulu, Hawaii, United States
  • University of Hawaii Cancer Center Honolulu, Hawaii, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

NCT05092958

Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, +30 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Sutter Auburn Faith Hospital Auburn, California, United States
  • Alta Bates Summit Medical Center-Herrick Campus Berkeley, California, United States
  • Palo Alto Medical Foundation-Fremont Fremont, California, United States
View all 275 locations
View Trial Details
Active, Not Recruiting

Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer

NCT03237780

Conditions
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Locally Advanced Bladder Urothelial Carcinoma, +36 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Keck Medicine of USC Buena Park Buena Park, California, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope at Irvine Lennar Irvine, California, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

NCT04963153

Conditions
Carcinoma, Carcinoma, Transitional Cell, Female Urogenital Diseases, +36 more
Locations
  • Los Angeles General Medical Center Los Angeles, California, United States
  • USC / Norris Comprehensive Cancer Center Los Angeles, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View Trial Details
Active, Not Recruiting

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy

NCT04637594

Conditions
Carcinoma, Carcinoma, Transitional Cell, Locally Advanced Bladder Urothelial Carcinoma, +12 more
Locations
  • Anchorage Associates in Radiation Medicine Anchorage, Alaska, United States
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
View all 377 locations
View Trial Details

Related conditions